Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?

ABBV eyes a strong Q1 performance as neuroscience sales, led by Botox and Vraylar, are set to jump 22%, with newer drugs helping offset declines in legacy treat

AbbVie ABBV is set to report first-quarter 2026 results on April 29. While the company’s immunology portfolio will remain the primary focus, its neuroscience segment is expected to contribute meaningfully to overall revenue growth.

AbbVie’s neuroscience portfolio includes Botox Therapeutic, depression drug Vraylar, oral migraine treatments Qulipta and Ubrelvy, and the recently launched Parkinson’s disease (“PD”) therapy Vyalev. The segment has become an increasingly important growth driver, supported by continued demand across key brands and contributions from newer assets.

AbbVie expects neuroscience revenues of approximately $2.8 billion in the first quarter. The Zacks Consensus Estimate for the segment is pegged at $2.79 billion, indicating growth of around 22% year over year. Higher sales of Botox Therapeutic,........

© Quartz